Patents Issued in June 7, 2016
  • Patent number: 9358213
    Abstract: The present invention relates to pharmaceutical compositions of duloxetine or pharmaceutically acceptable salts thereof, and processes for their preparation.
    Type: Grant
    Filed: April 19, 2008
    Date of Patent: June 7, 2016
    Assignee: WOCKHARDT LIMITED
    Inventors: Girish Kumar Jain, Chandrashekhar Kandi, Vishwanath Nande
  • Patent number: 9358214
    Abstract: A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration—time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
    Type: Grant
    Filed: June 2, 2003
    Date of Patent: June 7, 2016
    Assignee: ADARE Pharmaceuticals, Inc.
    Inventors: Phillip J. Percel, Krishna S. Vishnupad, Gopi M. Venkatesh
  • Patent number: 9358215
    Abstract: This application provides a high throughput method of making nanoparticles that utilizes plates comprising wells (e.g., 96-well plates).
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: June 7, 2016
    Assignee: BIND THERAPEUTICS, INC.
    Inventor: David M. Dewitt
  • Patent number: 9358216
    Abstract: Methods and formulations for infusing bioavailable resveratrol tinctures into food, beverage, cosmetic or drug products with minimal effect on the alcohol by volume of the product is provided. A resveratrol tincture includes an amount of trans-resveratrol mixed with a solvent of pure, or majority by weight, ethanol. The tincture is added to various food and beverages to make a bioavailable amount of trans-resveratrol to be absorbed and metabolized by the body providing demonstrated health benefits.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 7, 2016
    Assignee: Heart Healthy Spirits, LLC
    Inventors: Jeffrey J Keaffaber, Kim A. Popejoy
  • Patent number: 9358217
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for reducing blood levels of one or more of triglycerides (TG), total cholesterol (TC) and low density lipoprotein (LDL) in human subjects.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: June 7, 2016
    Assignee: MediciNova, Inc.
    Inventor: Kazuko Matsuda
  • Patent number: 9358218
    Abstract: The present invention relates to use of a tall oil fatty acid which is modified by saponification in enhancing rumen fermentation and/or lowering rumen methane production.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: June 7, 2016
    Assignee: Hankkija Oy
    Inventors: Juhani Vuorenmaa, Hannele Kettunen
  • Patent number: 9358219
    Abstract: A pharmaceutical composition comprises an active ingredient dissolved in an essentially non-aqueous carrier system comprising volatile and non-volatile components, in which the volatile component comprises a volatile non-solvent for the active ingredient and a volatile solvation additive for the non-solvent and the non-volatile component comprises a non-volatile non-solvent and optionally a non-volatile solvent for the active ingredient, the volatile and non-volatile non-solvents comprising silicone fluids of respectively different viscosity.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: June 7, 2016
    Assignee: Futura Medical Developments Limited
    Inventor: Adrian Francis Davis
  • Patent number: 9358220
    Abstract: The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: June 7, 2016
    Assignee: THESAN PHARMACEUTICALS, INC.
    Inventor: Jean Hilaire Saurat
  • Patent number: 9358221
    Abstract: The present invention discloses a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same; the composition comprises monascin or ankaflavin, or a combination thereof; the manufacturing method comprises the steps of: treating a Monascus fermented product with acetone for three times; elevating the concentration of the Monascus fermented product by a process of decompress concentration; and extracting the monascin and the ankaflavin from the Monascus fermented product with a silica gel column chromatography, a Sephadex LH-20 column chromatography, the silica gel column chromatography, and a preparative high performance liquid chromatography sequentially.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: June 7, 2016
    Assignee: SUNWAY BIOTECH CO., LTD.
    Inventors: Tzu-Ming Pan, Chun-Lin Lee, Cheng-Lun Wu
  • Patent number: 9358222
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: June 7, 2016
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
  • Patent number: 9358223
    Abstract: An implantable drug depot useful for preventing, reducing or treating bleeding at a surgical site beneath the skin in a patient is provided. The implantable drug depot comprises a therapeutically effective amount of clonidine or a pharmaceutically acceptable salt thereof, and at least one biodegradable polymer. The drug depot is capable of releasing clonidine or a pharmaceutically acceptable salt thereof over a period of at least three days.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: June 7, 2016
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Vanja Margareta King
  • Patent number: 9358224
    Abstract: Pharmaceutical formulations to be administered by pressurized metered dose inhalers (pMDIs), comprising a compound of general formula (I) may be used for the treatment and/or prevention of inflammatory or obstructive airway diseases.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: June 7, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Elena Losi, Enrico Zambelli
  • Patent number: 9358225
    Abstract: Ataxia-telangiectasia (A-T) is a progressive degenerative disorder that results in major neurological disability. In A-T patients, necropsy has revealed atrophy of all cerebellar cortical layers with extensive Purkinje and granular cell loss. We have previously identified an increase in phospho-p38MAPK levels, which was accompanied by downregulation of Bmi-1 and upregulation of p21, as key components of the mechanism causing defective proliferation of neural stem cells (NSCs) isolated from subventricular zone (SVZ) of Atm-null mice. Our results demonstrate that restoration of NSCs by pharmacologic inhibition of p38MAPK signaling has the potential to treat neurological defects of A-T. This study provides new insights into the therapeutic strategy targeting NSCs rather than replacing impaired neurons not only for A-T, but for other neurodegenerative disorders as well.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 7, 2016
    Assignee: Bach Pharma, Inc.
    Inventor: Paul K. Y. Wong
  • Patent number: 9358226
    Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogs of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: June 7, 2016
    Assignees: Emory University, The United States of America as represented by the Department of Veterans Affairs
    Inventor: Jack L. Arbiser
  • Patent number: 9358227
    Abstract: Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives are disclosed. Specifically, the 6-amino quinazoline or 3-cyano quinoline derivatives presented by general formula (I), or tautomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or metabolites, metabolic precursors or prodrugs thereof, are protein kinase inhibitors, in which each substitutent group of general formula (I) is as defined in the specification.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: June 7, 2016
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xin Li, Bin Wang
  • Patent number: 9358228
    Abstract: Combinations of netupitant and palonosetron, and methods of using such combinations to treat various pain states and irritable bowel syndrome, are provided.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: June 7, 2016
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Claudio Pietra, Sergio Cantoreggi
  • Patent number: 9358229
    Abstract: Provided herein is a combination therapy comprising a JAK kinase inhibitor and a dual PI3K/mTOR inhibitor, as well as methods of treating various cancers through the use of such a combination therapy.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: June 7, 2016
    Assignees: Novartis Pharma AG, Incyte Corporation
    Inventors: Alessandro M. Vannucchi, Costanza Bogani, Niccolo Bartalucci
  • Patent number: 9358230
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: June 7, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Frank S. Caruso, Huai-Hung Kao
  • Patent number: 9358231
    Abstract: The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: June 7, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., University of Miami
    Inventors: Nathanael Gray, Hwan Geun Choi, Xianming Deng, Jianming Zhang, Izidore Lossos
  • Patent number: 9358232
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: June 7, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Kristen Mae Hege, Rajesh Chopra
  • Patent number: 9358233
    Abstract: The present invention relates to the use of BI 6727 or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) comprising the administration of a high dose of BI 6727 according to a specific dosage schedule, optionally in combination with cytarabine.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: June 7, 2016
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tillmann Taube, Gerd Munzert, Dorothea Rudolph
  • Patent number: 9358234
    Abstract: This invention provides methods for preparing novel mammalian multipotent stem cells (MSCs), compositions thereof, and methods of preparing and administering the cells.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: June 7, 2016
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Kiminobu Sugaya, Tingyu Qu, Ankur V. Vaghani, Christopher Brannen, Hojoong M. Kim, Jose S. Pulido, Xiajing Dong
  • Patent number: 9358235
    Abstract: The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 7, 2016
    Assignee: Plexxikon Inc.
    Inventors: Gideon Bollag, Klaus-Peter Hirth, Prabha N. Ibrahim, Paul Lin, Brian West
  • Patent number: 9358236
    Abstract: The present invention relates to a combination of an allosteric mTOR inhibitor and a catalytic mTOR inhibitor for use in the prevention or treatment of neurodegenerative diseases, for example Huntington's Disease, and products and pharmaceutical compositions comprising such a combination for use in the prevention or treatment of such neurodegenerative diseases.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: June 7, 2016
    Assignee: Novartis AG
    Inventors: Leon Murphy, Jvan Galimberti
  • Patent number: 9358237
    Abstract: Disclosed are noribogaine compositions comprising a very high level of the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and not more than 0.5 wt % of ibogaine relative to the total amount of noribogaine.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: June 7, 2016
    Assignee: DEMERX, INC.
    Inventors: Robert M. Moriarty, Deborah C. Mash
  • Patent number: 9358238
    Abstract: A method of enhancing the performance of chicken comprising administering zilpaterol to the chicken wherein the concentration of zilpaterol is from about 1 ppm to about 13 ppm and is administered every day for a period of about 7 to about 21 days.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: June 7, 2016
    Assignee: Intervet Inc.
    Inventor: John A. Rogers
  • Patent number: 9358239
    Abstract: The accumulation of abnormal proteins in neurodegenerative disorders is considered to induce oxidative stress and lead to cell death. Thus suppression of abnormal protein aggregation and reducing oxidative stress or reactive oxygen species (ROS) are expected to inhibit a wide range of harmful downstream events, providing an observation for identifying the potential prevention and treatment of neurodegenerative disorders comprising spinocerebellar ataxia (SCA), Alzheimer's disease (AD) or Parkinson's disease (PD). In the present invention, there are several cell and animal experiment models for SCA, AD and PD established, and NiSOD-like compounds were applied to these experiment models. The results have demonstrated how NiSOD-like compounds are likely to work in suppressing abnormal protein aggregation, recovering cell viability, increasing mature neuron number and neurite outgrowth length and protecting dopaminergic cells by reducing oxidative stress or reactive oxygen species in brain tissues.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 7, 2016
    Assignee: National Taiwan Normal University
    Inventors: Way-Zen Lee, Guey-Jen Lee, Hsiu-Mei Hsieh, Chien-Wei Chiang, Bin Huang, Yaw-Syan Fu, Yun-Ming Wang
  • Patent number: 9358240
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: June 7, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Patent number: 9358241
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: June 7, 2016
    Assignee: LIPOCINE INC.
    Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V Patel
  • Patent number: 9358242
    Abstract: Calcium glycerophosphate is found to be effective in treating and preventing a disease, disorder and/or condition of the respiratory system. The disease, disorder and/or condition is related to an obstructive or a restrictive condition of the respiratory airway.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: June 7, 2016
    Assignee: Prelief Inc.
    Inventors: Alan E. Kligerman, Margaret T. Weis
  • Patent number: 9358243
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: June 7, 2016
    Assignee: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
  • Patent number: 9358244
    Abstract: The present invention relates to solid dosage forms of oleyl phosphocholine (C18:1-PC), or OlPC, for oral administration. Further, the present invention relates to methods for the preparation of the present solid dosage forms and the use thereof as a medicament and especially a medicament for treatment of parasitic diseases, such as leishmaniasis, chagas and malaria, and cancer both in humans and animals. Specifically, the present invention relates to a solid dosage form comprising: 6 to 25 weight % of the solid dosage form oleyl phosphocholine; 20 to 35 weight % of the solid dosage form lactose; 35 to 50 weight % of the solid dosage form cellulose; 5 to 20 weight % of the solid dosage form croscarmellose; 1 to 10 weight % of the solid dosage form hydroxypropylmethyl cellulose; and 0.05 to 1 weight % of the solid dosage form of a lubricant.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: June 7, 2016
    Assignee: Oblita Therapeutics BVBA
    Inventors: Frans Herwig Jansen, Bruno Jansen
  • Patent number: 9358245
    Abstract: Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufacture of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: June 7, 2016
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Henry C. Lin
  • Patent number: 9358246
    Abstract: A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following Structural Formula (A), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: June 7, 2016
    Assignees: Microbial Chemistry Research Foundation, The University of Tokyo
    Inventors: Ryoichi Matsuda, Masataka Shiozuka, Akira Wagatsuma, Yoshikazu Takahashi, Daishiro Ikeda, Yoshiaki Nonomura, Masafumi Matsuo, Atsushi Nishida
  • Patent number: 9358247
    Abstract: The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: June 7, 2016
    Assignee: Oncology Research International Limited
    Inventors: Michael John Story, Kenneth Michael Wayte
  • Patent number: 9358248
    Abstract: Oligonucleotide analogs are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2?-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogs rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogs can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogs and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogs, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: June 7, 2016
    Assignee: ASTEX PHARMACEUTICALS, INC.
    Inventors: Pasit Phiasivongsa, Sanjeev Redkar
  • Patent number: 9358249
    Abstract: In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: June 7, 2016
    Assignee: The Regents of the University of California
    Inventors: Jing Huang, Rui Hao, Brett Eugene Lomenick, Nao Jonai, Simon Diep
  • Patent number: 9358250
    Abstract: Provided herein are therapies for the treatment of pathological conditions, such as cancer, and method of using SCD1 antagonists.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: June 7, 2016
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Xiangnan Du, Jing Qing
  • Patent number: 9358251
    Abstract: The invention relates to a method for dissolving the components of gel forming materials suitable for use in wound care comprising the steps of admixing said components with an ionic liquid. The ionic liquid may be selected from the group of tertiary amine N-oxides, N,N-dimethyl formamide/nitrogen tetroxide mixtures, dimethyl sulphoxide/paraformaldehyde mixtures and solutions of limium chloride in N,N-dimethyl acetamide or N-methyl pyrrolidone.
    Type: Grant
    Filed: November 22, 2007
    Date of Patent: June 7, 2016
    Assignee: CONVATEC TECHNOLOGIES INC.
    Inventors: David Kershaw, Simon Adams
  • Patent number: 9358252
    Abstract: Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: June 7, 2016
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Mallikarjun Sundaram, Takashi Kei Kishimoto, Sucharita Roy
  • Patent number: 9358254
    Abstract: A method of treating or preventing Helicobacter pylori infection in a subject, includes the step of orally administering to the subject a composition including a carbonaceous material that has a pore defined therein which has a radius of more than 0 nm but less than 2.5 nm; and from 0.001-15% by weight, based on weight of the carbonaceous material, of an active particle coated that is on the carbonaceous material and that is made of a material selected from the group consisting of silver, gold, aluminum, zinc, copper, and titanium dioxide.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: June 7, 2016
    Assignee: FENG CHIA UNIVERSITY
    Inventor: Tse-Hao Ko
  • Patent number: 9358255
    Abstract: The invention is directed to a method for isolating stromal cells to form a therapeutic composition; and administering said therapeutic composition to the subject. A further embodiment of the invention is directed to therapeutic compositions comprising isolated stromal cells.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: June 7, 2016
    Assignee: SpineSmith Partners, L.P.
    Inventors: Kevin Dunworth, Richard J. Kana, Theodore Sand, Matthew Murphy
  • Patent number: 9358256
    Abstract: A gap-patterned wound dressing, including a patterned foam structure having a gap patterned side and a non-gap patterned side, wherein the gap patterned side includes a pattern of foam gaps disposed between foam areas dosed with honey, where the pattern of foam gaps is formed by the honey dosed areas; and wherein a wound in contact with the gap patterned side discharges an exudate which substantially collects in the individual ones of the foam gaps causing honey in the individual ones of the honey dosed areas to be substantially dispersed throughout a wound treatment zone.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: June 7, 2016
    Assignee: Links Medical Products, Inc.
    Inventors: Greg Devenish, Howard Kenneth Payne
  • Patent number: 9358257
    Abstract: A serum resistin level reducing agent that comprises a cell wall disrupted product of a Chlorella pyrenoidos, and that reduces a serum resistin level, as an agent for oral administration. A food or beverage composition for reducing a serum resistin level that comprises a cell wall disrupted product of a Chlorella pyrenoidos, and that reduces a serum resistin level. A method of reducing a serum resistin level by applying a cell wall disrupted product of a chlorella for oral administration. A use of a cell wall disrupted product of a chlorella for oral administration for reducing a serum resistin level.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: June 7, 2016
    Assignee: SUN CHLORELLA CORP.
    Inventors: Hiroshige Itakura, Tetsuaki Nakayama, Ryo Matoba
  • Patent number: 9358258
    Abstract: The present invention relates to a novel bacteriophage having an E. coli-specific bactericidal activity, a composition for the prevention or treatment of infectious diseases caused by Enterotoxigenic E. coli comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, a feed additive composition comprising the bacteriophage as an active ingredient, a sanitizer or cleaner comprising the bacteriophage as an active ingredient, and a method for treating colibacillosis using the bacteriophage. The novel bacteriophage of the present invention has a specific bactericidal activity against pathogenic E. coli, and excellent acid- and heat-resistance. Therefore, the novel bacteriophage can be used for the prevention or treatment of swine colibacillosis, which is an infectious disease caused by pathogenic E. coli, and can also be widely used in animal feed additive compositions, sanitizers, and cleaners.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: June 7, 2016
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Jae Won Kim, Young Wook Cho, Eun Mi Shin, Young Sa Kim, Si Yong Yang
  • Patent number: 9358259
    Abstract: A process and apparatus for extracting cannabinoids from cannabis plant material plant material and for transporting low concentrations of cannabinoids in a solution of solvent includes at least a solvent tank, a hopper, and one or more pumps. A plurality of valves may also be incorporated into the invention. Plant material may be soaked, washed, and/or rinsed with a solvent that extracts essential elements from cannabis plant matter. The process minimally includes filling a hopper with plant mater, moving solvent from a solvent tank to the hopper, and moving solvent back to the solvent tank after an extraction. Repeating this process a plurality of times with new plant material increases the concentration cannabinoids in the solvent tank after each time the process is performed.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: June 7, 2016
    Inventors: Andrew David Hospodor, Robert James Rapp
  • Patent number: 9358260
    Abstract: The present invention relates to a process for obtaining a Labisia pumila water extract comprising the steps of: obtaining an extract from dried Labisia pumila plant material using water extraction, filtering the extract to obtain filtrate and Labisia pumila plant material residue, re-extracting the Labisia pumila residue using water extraction, centrifuging the Labisia pumila extracts to obtain a supernatant, characterized in that, the Labisia pumila plant material includes leaves and roots in a ratio of 3:2 by weight and ratio of the dried plant material to water used in the water extraction process is 1:10 by weight, wherein the yield obtained from initial extraction is 7% to 8% and the extra yield obtained from re-extraction is 33% to 38% and the total yield obtained from the extraction is 10% to 12%.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: June 7, 2016
    Assignee: PHARMANIAGA BHD
    Inventors: Defri bin Zulkarnaini, Noridayu Che Ani, Miau Ching Ho, Visweswaran Navaratnam, Venkatesh Gantala
  • Patent number: 9358261
    Abstract: An Alternative ACT composition consisting of natural botanical active ingredients, all of which are GRAS (generally regarded as safe by the FDA). The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives, berberine, capsaicin, and papaya extract. The four active substances mixed with various selected excipient compounds to form a single pill, tablet or capsule for the treatment and prevention of chikungunya.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: June 7, 2016
    Assignee: U.S. Phytotherapy, Inc.
    Inventor: Bob Rosen
  • Patent number: 9358262
    Abstract: A method of treating or preventing diabetes or obesity that comprises administering an antioxidant-enriched composition produced by fermenting fruit extracts with the bacteria Serratia vaccinii. The antioxidant-enriched composition is capable of decreasing plasma glucose levels, increasing circulating adiponectin levels and decreasing hyperphagia in a subject.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: June 7, 2016
    Assignee: University of Ottawa
    Inventors: Chantal Matar, Pierre S. Haddad
  • Patent number: 9358263
    Abstract: Personal care composition comprising at least one extract selected from the group consisting of extracts of Terminalia bellerica, Butea monosperma, Mallotus philippinensis, Anogeissus latifolia, Innula racemosa, Ficus benghalensis, Nerium indicum, Psoralea corylifolia, Acacia catechu, Abies pindrow, Cedrus deodara, Emblica officinalis, Moringa oleifera, Glycyrrhiza glabra, and mixtures thereof, and a dermatologically acceptable carrier. Additionally or alternatively, the composition may comprise 2-hexyldecanol.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: June 7, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Cheri Lynn Millikin, Laura Jackson Goodman, Donald Lynn Bissett, Larry Richard Robinson, Rosemarie Osborne